ANDA 78579, held by Hospira. Levofloxacin.
As of Nov 16, 2026, ANDA 78579 (Levofloxacin In Dextrose 5% In Plastic Container), held by Hospira, was first approved by FDA on Sep 3, 2015, with 5 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 3, 2015 | Original application | Approved | None posted |
| Levofloxacin In Dextrose 5% In Plastic ContainerEQ 250MG/50ML (EQ 5MG/ML) · injectable;injection | Levofloxacin | Rx |
| Levofloxacin In Dextrose 5% In Plastic ContainerEQ 500MG/100ML (EQ 5MG/ML) · injectable;injection | Levofloxacin | Rx |
| Levofloxacin In Dextrose 5% In Plastic ContainerEQ 750MG/150ML (EQ 5MG/ML) · injectable;injection | Levofloxacin | Rx |
| Sep 20, 2024 | Supplement 9Labeling · Standard review | Approved | None posted |
| May 3, 2019 | Supplement 6Labeling · Standard review | Approved | None posted |
| Oct 18, 2018 | Supplement 5Labeling · Standard review | Approved | None posted |
| Oct 15, 2018 | Supplement 2Labeling · Standard review | Approved | None posted |
| Oct 15, 2018 | Supplement 4Labeling · Standard review | Approved | None posted |
| Sep 3, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters